Stocks and Investing
Stocks and Investing
Thu, March 28, 2024
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Michael Schmidt Initiated (ADCT) at Strong Buy and Held Target at $11 on, Mar 28th, 2024
Michael Schmidt of Guggenheim, Initiated "ADC Therapeutics SA" (ADCT) at Strong Buy and Held Target at $11 on, Mar 28th, 2024.
Michael has made no other calls on ADCT in the last 4 months.
There are 2 other peers that have a rating on ADCT. Out of the 2 peers that are also analyzing ADCT, 0 agree with Michael's Rating of Hold.
These are the ratings of the 2 analyists that currently disagree with Michael
- Gregory Renza of "RBC Capital" Reiterated at Buy and Held Target at $8 on, Thursday, March 14th, 2024
- Robert Burns of "HC Wainwright & Co." Reiterated at Strong Buy and Held Target at $9 on, Wednesday, March 6th, 2024
Contributing Sources